Susquehanna International Group, LLP Aurinia Pharmaceuticals Inc. Put Options Transaction History

Susquehanna International Group, LLP

$568 Billion
Q1 2024

Put Options

27 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 07, 2024	BUY	$4.93 - $9.31 $677,875 - $1.28 Million	137,500 Added 40.01%	481,200 $2.41 Million
Q4 2023 Feb 14, 2024	BUY	$7.13 - $9.49 $491,970 - $654,810	69,000 Added 25.12%	343,700 $3.09 Million
Q3 2023 Nov 14, 2023	SELL	$7.77 - $12.27 $2.75 Million - $4.34 Million	-353,600 Reduced 56.28%	274,700 $2.13 Million
Q2 2023 Aug 11, 2023	SELL	$8.96 - $11.69 $809,984 - $1.06 Million	-90,400 Reduced 12.58%	628,300 $6.08 Million
Q1 2023 May 16, 2023	BUY	$5.94 - $11.27 $245,916 - $466,578	41,400 Added 6.11%	718,700 $7.88 Million

Q4 2022 Feb 14, 2023	SELL	$4.11 - $8.14 $321,813 - $637,362	-78,300 Reduced 10.36%	677,300 $2.93 Million
Q3 2022 Nov 14, 2022	SELL	$6.66 - $12.39 $2.56 Million - $4.76 Million	-384,400 Reduced 33.72%	755,600 $5.68 Million
Q2 2022 Aug 15, 2022	SELL	$8.95 - $12.8 $2.5 Million - $3.57 Million	-278,800 Reduced 19.65%	1,140,000 $11.5 Million
Q1 2022 May 16, 2022	SELL	$10.05 - $22.48 $3.3 Million - $7.38 Million	-328,500 Reduced 18.8%	1,418,800 $17.6 Million
Q4 2021 Feb 14, 2022	SELL	$17.78 - $33.08 $844,550 - $1.57 Million	-47,500 Reduced 2.65%	1,747,300 $40 Million
Q3 2021 Nov 15, 2021	BUY	$10.93 - $23.55 $2.61 Million - $5.63 Million	238,900 Added 15.35%	1,794,800 $39.7 Million
Q2 2021 Aug 11, 2021	BUY	$10.0 - $14.52 $4.62 Million - $6.71 Million	462,400 Added 42.29%	1,555,900 $20.2 Million
Q1 2021 May 17, 2021	SELL	$12.3 - $18.73 $119,310 - $181,681	-9,700 Reduced 0.88%	1,093,500 $14.2 Million
Q4 2020 Feb 16, 2021	BUY	$12.94 - $16.05 $4.87 Million - $6.04 Million	376,600 Added 51.83%	1,103,200 $15.3 Million
Q3 2020 Nov 16, 2020	BUY	$13.19 - $16.66 $3.7 Million - $4.68 Million	280,800 Added 62.99%	726,600 $10.7 Million
Q2 2020 Aug 14, 2020	BUY	$14.12 - $18.33 $577,508 - $749,696	40,900 Added 10.1%	445,800 $7.24 Million
Q1 2020 May 15, 2020	SELL	$11.34 - $21.46 $1.54 Million - $2.91 Million	-135,400 Reduced 25.06%	404,900 $5.88 Million
Q4 2019 Feb 14, 2020	SELL	$3.88 - $21.42 $779,492 - $4.3 Million	-200,900 Reduced 27.1%	540,300 $10.9 Million
Q3 2019 Nov 14, 2019	BUY	$5.34 - $6.59 $1.55 Million - $1.91 Million	290,400 Added 64.42%	741,200 $3.96 Million
Q2 2019 Aug 14, 2019	BUY	$6.05 - $6.75 $89,540 - $99,900	14,800 Added 3.39%	450,800 $2.97 Million
Q1 2019 May 15, 2019	BUY	$6.06 - $7.64 $1.66 Million - $2.09 Million	273,900 Added 168.97%	436,000 $2.83 Million
Q4 2018 Feb 14, 2019	SELL	$5.08 - $6.83 $89,408 - $120,208	-17,600 Reduced 9.79%	162,100 $1.11 Million
Q3 2018 Nov 14, 2018	SELL	$5.27 - $6.64 $269,824 - $339,968	-51,200 Reduced 22.17%	179,700 $1.19 Million
Q2 2018 Aug 14, 2018	SELL	$5.06 - $6.36 $75,394 - $94,764	-14,900 Reduced 6.06%	230,900 $1.3 Million
Q1 2018 May 15, 2018	BUY	$4.85 - $5.99 $362,295 - $447,453	74,700 Added 43.66%	245,800 $1.28 Million
Q4 2017 Feb 14, 2018	SELL	$4.53 - $7.09 $155,379 - $243,187	-34,300 Reduced 16.7%	171,100 $775,000
Q3 2017 Nov 14, 2017	BUY	$5.71 - $6.9 $1.17 Million - $1.42 Million	205,400	205,400 $1.29 Million

Others Institutions Holding AUPH

# of Institutions

205

Shares Held

55.6M

Call Options Held

838K

Put Options Held

1.18M

Armistice Capital, LLC New York, NY

12.3M
Shares

$70 Million
0.84% of portfolio
Black Rock Inc. New York, NY

8.66M
Shares

$49.5 Million
0.0% of portfolio
Nea Management Company, LLC Timonium, MD

3.97M
Shares

$22.7 Million
1.4% of portfolio
State Street Corp Boston, MA

2.77M
Shares

$15.8 Million
0.0% of portfolio
Goldman Sachs Group Inc New York, NY

2.15M
Shares

$12.3 Million
0.0% of portfolio

View Full List

About Aurinia Pharmaceuticals Inc.

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $810M
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

More about AUPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account